Prokaryotics
Private Company
Funding information not available
Overview
Prokaryotics is a private, pre-clinical biotech startup tackling the global antibiotic resistance crisis by developing new classes of antibiotics that target Gram-negative and Gram-positive bacteria. The company's strategy centers on inhibiting cell envelope assembly, a fundamental and conserved bacterial process, to overcome intrinsic resistance mechanisms. Founded by ex-Merck antimicrobial discovery leaders, Prokaryotics leverages licensed assets, deep physiological expertise, and innovative screening to advance its pipeline.
Technology Platform
Integrated discovery platform focused on bacterial physiology and cell envelope biogenesis, leveraging genetics, genomics, chemical biology, and phenotypic screening to identify novel targets and antibiotic candidates.
Opportunities
Risk Factors
Competitive Landscape
Prokaryotics competes in the niche but critical space of novel antibiotic discovery against multidrug-resistant bacteria. Competitors include other small biotechs (e.g., Entasis Therapeutics, now part of Innoviva; Spero Therapeutics) and large pharma with remaining antibiotic units (e.g., Pfizer, GSK). Its differentiation lies in its specific focus on cell envelope biogenesis and its foundational assets and team from Merck.